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Chronic renal allograft rejection: Immunologic and nonimmunologic
risk factors. The pathogenesis of chronic renal allograft rejection is
unknown. It is also unclear why cyclosporine has failed to prevent chronic
rejection. We examined possible risk factors for graft loss to chronic
rejection among 706 renal transplants using the Cox proportional hazards
model with fixed and time-dependent covariates. Both the number and the
severity of acute rejection episodes were independent risk factors for
chronic rejection [relative risk (95% confidence interval) 2.31 (2.04 to
2.60) and 1.53 (1.27 to 1.84), respectively]. Cyclosporine and cyclosporine
withdrawal had no effect on chronic rejection. Acute rejections occurring
within the first three months after transplantation, when cyclosporine most
effectively prevented acute rejection, also had no effect on chronic
rejection. Risk factors that were independent of acute rejection and not
clearly attributable to immune mechanisms included serum albumin [0.20
(0.10 to 0.38) for each g/dl], proteinuria [1.42 (1.29 to 1.57) for each g124
hr], and serum triglycerides [1.09 (1.03 to 1.16) for each 100 mgldl]. These
results suggest that the reduction in acute rejection episodes from
cyclosporine has failed to reduce graft failure from chronic rejection,
possibly because the early (within the first 3 months) and mild acute
rejection episodes that are most effectively prevented by cyclosporine do
not cause chronic rejection. In addition, the results suggest that there may
be a number of nonimmunologic risk factors for chronic rejection.
Major advances in immunosuppression, including the introduc-
tion of cyclosporine, have led to dramatic improvements in
short-term renal allograft survival [1, 2]. Unfortunately, the rate of
late graft failure from chronic rejection has not changed [3—5].
Both immune and nonimmune factors have been implicated in the
pathogenesis of chronic rejection [6—101. It has been shown that
acute rejection episodes are strong predictors of chronic rejection
[7, 11—13]. However, despite dramatic reductions in the incidence
of acute rejection with the widespread adoption of cyclosporine
[14—16], the incidence of chronic rejection has remained un-
changed [3—5, 17].
Previous investigations examining potential causes or risk fac-
tors for chronic rejection have focused on relatively few variables
occurring at or soon after transplantation [10, 12, 16, 18—21].
Some of these studies were limited by their reliance on univariate
statistical techniques that do not distinguish between confounding
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effects of multiple variables [10, 18, 20]. None of the investigations
have examined the potential effects of risk factors occurring
throughout the late post-transplant period. Therefore, we ex-
plored the relationship between graft loss to chronic rejection and
acute rejection, cyclosporine use and other immune and nonim-
mune risk factors in a large cohort of transplant recipients with
long-term follow-up. We used the Cox proportional hazards
model with time-dependent covariates to explore the complex
interrelationships between these variables in the early and late
post-transplant period. Although it is difficult to discern cause and
effect relationships in retrospective analyses, it appeared that
cyclosporine reduced acute rejection within the first three months
after transplantation. Nevertheless, the use of cyclosporine and
acute rejection episodes during the first three months were poor
predictors of graft loss to chronic rejection. Rather, acute rejec-
tion episodes after three months and a number of other risk
factors were better predictors of chronic rejection.
Methods
Patient population
Between January 1, 1976, and June 1 1991, 769 patients
received 838 renal transplants at Hennepin County Medical
Center, Minneapolis, Minnesota. Since we were examining
chronic rejection, only 675 patients who received 706 renal
allograft that survived for at least six months were included. All
patients were followed to death, return to dialysis, or January 1,
1995.
Immunosuppression
Prior to 1986, patients were treated with a prophylactic immu-
nosuppression protocol that has previously been described in
detail [22]. Briefly, Minnesota antilymphocyte globulin was used
in conjunction with high-dose corticosteroids and azathioprine.
Long-term maintenance immunosuppression used prednisone (15
mg/day or 15 mg every other day), and azathioprine (2 mg/kg/day
adjusted for leukopenia). In 1986 sequential quadruple immuno-
suppression with cyclosporine was adopted [23]. In patients
without acute rejection episodes for at least one year, cyclosporine
was routinely discontinued [23]. Successful discontinuation of
cyclosporine was followed by prednisone reduction to 15 mg every
other day in stable patients.
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Clinical data
Acute rejection was defined as an unexplained rise in serum
creatinine (at least 30% from the baseline) that either responded
to treatment with intravenous corticosteroids or was confirmed by
biopsy (38%). The percentage of acute rejection episodes con-
firmed by biopsy varied according to the time after transplant:
only 25% for the acute rejection episodes occurring in first three
months after transplantation, but 57% for the acute rejection
episodes occurring more than two years after transplantation.
Severe acute rejection was defined as a greater than 50% decline
in serum creatinine-estimated glomerular filtration rate [(1/creat-
mine before acute rejection episode — 1/creatinine peak)/(1/
creatinine before acute rejection episode) X 100]. Chronic rejec-
tion was defined as a gradual, progressive decline in renal function
leading to return to dialysis, and was confirmed by renal histology
in 84% [24]. Histological definition of chronic rejection included
tubulointerstitial and vascular modifications and excluded recur-
rent glomerulonephritis [24]. Ureteral obstruction was excluded
by ultrasound.
Pretranspiant data on multiple immune and nonimmune vari-
ables included: age, gender, race, major causes of end-stage renal
disease (diabetes, autosomal dominant polycystic kidney disease,
and glomerulonephritis), weight, height, body mass index (kg/rn2),
donor age, donor gender, donor source (cadaveric vs. living
related), pretransplant splenectomy, pretransplant bilateral ne-
phrectomy, prior transplant, pretranspiant blood transfusions,
percent panel reactive antibodies at peak and at transplant,
number of AB (0, 1, 2, 3, and 4) and DR (0, 1, and 2) mismatches,
cigarette smoking history, immunosuppressive agents used during
the period of induction, that is, cyclosporine and Minnesota
antilymphocyte globulin, and delayed graft function.
Post-transplant clinical and laboratory data were also exam-
ined, including: blood pressure (normotensive if less than 130/90
mm Hg without treatment, mild hypertension if at least 130/90
mm Hg and/or requiring treatment with a single agent, and more
severe hypertension if requiring treatment with two or more
agents), serum creatinine, 24-hour creatinine clearance, serum
albumin, total cholesterol, triglycerides, high density lipoprotein
cholesterol (HDL), and 24-hour urine protein excretion. These
variables were each recorded at three months, six months, one
year, and then annually until last follow-up. Also recorded
was whether or not patients were being treated with specific
antihypertensive drugs (angiotensin converting enzyme inhibitors,
beta-blockers, calcium channel blockers, and diuretics), and anti-
lipemic agents [3-hydroxy-3-methylglutaryl coenzyme A (HMG-
C0A) reductase inhibitors]. Major posttransplant event variables
included: acute rejection episodes, cytomegalovirus infection
(subclinical with only serological modifications, clinical with only
fever, symptomatic including pancytopenia, elevated liver en-
zymes, gastrointestinal bleeding, and/or pneumonia), the devel-
opment of post-transplant diabetes (requiring treatment with
insulin or an oral hypoglycemic agent), withdrawal of cyclospo-
rifle, and the reduction of prednisone from 15 mg/day to 15 mg
every other day.
Statistical analysis
To avoid bias from excluding cases with missing data, we
imputed missing values in the survival analysis. Missing values for
post-transplant variables were imputed as the average of values
occurring immediately before and after the missing value, when-
ever these values were known. Others were randomly imputed
assuming a normal distribution of missing values with the same
mean and SD as the known values at the same time of follow-up.
The percentages of values that were estimated as the means of
values before and after the missing value were: 5.7% for choles-
terol, 6.4% for triglycerides, 16.8% for HDL, 6.0% for serum
albumin, 5.3% for urine protein, and 1.3% for creatinine. The
percentages of values that were randomly imputed were: 4.8% for
cholesterol, 5.1% for triglycerides, 24.3% for HDL, 5.2% for
serum albumin, 8.5% for urine protein, and 2.6% for serum
creatinine. There were 6029 values for each post-transplant
variable.
The only pretranspiant variable with missing values was the
degree of DR mismatching. Values for DR were not known for
125 transplants (17.7%) performed before 1980. Since the number
of DR mismatches was associated with the number of AB
mismatches among the 581 cases in whom both were determined,
unknown DR mismatches were randomly imputed using the
conditional probabilities based on known AB mismatches. The
effects of the randomly imputed missing values were examined by
comparing the results derived from five separate data sets, each
with different randomly imputed missing values [25]. In every
case, the final Cox proportional hazards models derived from the
different randomly imputed data sets were virtually identical,
indicating that the random imputation had little impact on the
final results.
Differences between groups were examined using Student's
t-test, chi-square, and the log-rank method for comparing Kaplan-
Meier actuarial survival plots. Possible risk factors for chronic
rejection were first examined using univariate Cox proportional
hazards analysis. Covariates that tended to correlate with end-
points on univariate analysis (P < 0.15) were also examined using
multivariate Cox analysis. Post-transplant variables that could
assume different values at different times, such as cholesterol and
triglycerides, were treated as time-averaged, time-dependent co-
variates in the Cox analysis, whereby the value at any time was the
average of all values that occurred before that time. Discrete
post-transplant events, such as acute rejection, were also handled
as time-dependent covariates in the Cox analysis, and were
treated as being absent until the time of occurrence and then
present thereafter. Pretransplant variables were used as fixed
(discrete or parametric) covariates in the univariate and multiva-
nate Cox analysis. Since most cytomegalovirus infections occurred
within the first six months post-transplant when no endpoint had
been reached, this was also treated as a fixed covariate. Data were
analyzed using the statistical software packages SPSS and BMDP
[26, 27]. Final results were considered significant for P < 0.05.
Values are reported as mean SD, except as indicated.
Results
Patient population
There were 706 renal transplants performed in 675 patients
whose age at transplantation was 41 13 years. Follow-up was 7.0
4.2 (range 0.5 to 18) years. Of the patients studied 56.4% were
men, 4.1% were African American, and 3.1% were American
Indian. The cause of end-stage renal disease was diabetes in
28.2%, chronic glomerulonephritis in 33.9%, and autosomal dom-
inant polycystic kidney disease in 9.6%. There were 11.6% who
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Table 1. Independent risk factors for first acute rejection
Relative risk for
acute rejection
Variable (95Y( confidence interval) P value
Age (each decade) 0.92 (0.86—0.99) 0.024
Living related donor 0.71 (0.51—0.99) 0.042
Number of HLA-A, -B mismatches 1.14 (1.02—1.21) 0.025
Number of HLA-DR mismatches 1.16 (1.02—1.32) 0.021
Peak panel reactive antibodies 1.35 (1.04—1.74) 0.025
Symptomatic CMV infection' 1.53 (1.26—1.85) 0.000
Use of cyclosporine 0.65 (0.53—0.79) 0.000
Variables not predictive of acute rejection: gender, body mass index,
donor gender and age, pre-transplant blood transfusion. percent panel
reactive antibodies at transplant, delayed graft function, cause of end-
stage renal disease, and other immunosuppression agents used during the
period of induction. Relative risk is the risk of acute rejection compared
to no risk = 1.00.
hCMV, cytomegalovirus
had received a previous transplant and 11.2% who had live related
donors. Donor age was 31 13 (range 7 to 62) years. Only 2.5%
of donors were < 10 years old, and 9.2% were > 50 years old.
Donor matching was 37% male-to-male, 18% female-to-female,
25% male-to-female, and 19% female-to-male. Fifteen percent
had zero HLA-A,-B mismatches, and 64% had zero HLA-DR
mismatches. Pretranspiant splenectomy was performed in 68.1%,
but was largely abandoned in recent years. Bilateral nephrectomy
was performed prior to transplant in 30.9%.
All patients received azathioprine and corticosteroid-based
immunosuppression. Minnesota antilymphocyte globulin was
used for induction therapy in 88.7%. In 35.4% cyclosporine was
used as prophylactic immunosuppression once renal function was
established. For the maintenance therapy, cyclosporine doses
were adjusted to maintain a 12-hour trough level of 75 to 125
nglml (by high-performance liquid chromatography), and the
mean daily cyclosporine dose was 302 118 mg/day. In 79.6% of
patients without acute rejection episodes for at least one year,
cyclosporine was electively withdrawn at 1.2 0.4 years after
transplantation. The mean daily cyclosporine dose was 195 98
mg/day for the 20.4% patients left on cyclosporine. An attempt
was made to convert 63.8% of patients to alternate day pred-
nisone at 1.9 1.2 years after transplantation. However, 36.1%
returned to daily prednisone some time later, due to unstable
renal function. At last follow-up, 20.7% had returned to dialysis,
24.2% had died with a functioning graft, and 3.1% had been lost
to follow-up. Chronic rejection was the reason for return to
dialysis in 86.3%. The 10-year actuarial patient and graft survivals
were 72% and 53%, respectively.
Risk factors for acute rejection
Overall, 32% had none, 30% had only one, and 38% had more
than one episode of acute rejection. Among those with acute
rejection, 32.4% had severe acute rejection; 15.2% had one and
17.2% had two or more severe acute rejection episodes. Younger
age (for each decade older, the relative risk decreased by 8%),
cadaveric donors, HLA mismatches (for each of HLA mismatch,
the relative risk increased 14% for HLA-AB, and 16% for
HLA-DR), high peak panel reactive antibody (> 50%), symptom-
atic cytomegalovirus infection, and the use of conventional immu-
Table 2. Relationship between acute rejection and chronic rejection
c/ Of transplants withTime after . . Relative risk of acute
transplantation acute rejection rejection for CR
months CR No CR (95% confidence interval)
<3 57 44"
3—6
6—12
12—24
>24
Abbreviation is: CR, chronic rejection.
The percent of patients with acute rejection episodes, severe acute
rejection (greater than 50% reduction in renal failure) and multivariate
Cox relative risk (no risk = 1.00).
"P < 0.01P  0.000
nosuppression (without cyclosporine) were independent risk fac-
tors for the first acute rejection episode (Table 1).
Risk factors for chronic rejection
Both the number and severity of acute rejection episodes were
independent risk factors for chronic rejection (Table 3). To
determine whether the timing of acute rejection influenced
chronic rejection, we analyzed separately the effects of acute
rejection in different post-transplant time intervals. Acute rejec-
tion at three months did not cause chronic rejectionperse (Table
2). Even severe acute rejection at three months increased the risk
of chronic rejection only modestly [relative risk (95% confidence
interval) 1.90 (1.27 to 2.85), P < 0.011. In contrast, after three
months, and especially after 24 months, acute rejection was
associated with a much greater risk for chronic rejection (Table
2). The effect on chronic rejection of biopsy-confirmed acute
rejection was almost identical to that of acute rejection episodes
that were not confirmed by biopsy [1.74 (1.08 to 2.80) vs. 1.5 (1.07
to 2.20), respectively].
Cyclosporine as used in these patients had no effect on graft loss
to chronic rejection in either univariate or multivariate analysis
(Fig. 1). Although cyclosporine decreased the number of acute
rejection episodes in the first three months after transplantation,
it had no effect on acute rejection occurring greater than three
months after transplantation (Fig. 2). The incidence of acute
rejection episodes following cyclosporine withdrawal was not
greater than that in patients who never used cyclosporine with
comparable follow-up (> 1.2 years) (34% vs. 33%, P = NS). In
addition, acute rejection episodes occurring after cyclosporine
withdrawal [0.62 (0.36 to 1.09), P = NS] had no additional effect
on chronic rejection independently of the effect of acute rejection
episodes occurring in comparable follow-up period [17.68 (10.82
to 28.72), P < 0.0011.
Interestingly, donor source (living related donor vs. cadaveric),
but not donor age or donor gender, was a risk factor for chronic
rejection on univariate analysis [0.27 (0.10 to 0.73), P 0.006].
However, the influence of donor source was not independent of
acute rejection in the multivariate analysis (Table 3). Similarly,
the number of DR mismatches [1.25 (0.99 to 1.57), P =0.053] and
delayed graft function [1.41 (0.99 to 2.00), P = 0.051] both
appeared to be risk factors for chronic rejection on univariate
analysis, but their effects were not independent of acute rejection
and other risk factors in the multivariate analysis (Table 3).
25 7"
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40 13"
64 20
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Fig. 1. Association between cyclosporine and chronic rejection (Kaplan-
Meier plot). Cyclosporine versus no cyclosporine indicates patients who
were or were not initially treated with prophylactic cyclosporine after
transplantation regardless of subsequent immunosuppression, that is, by
intention to treat. Numbers indicate the number of patients analyzed at
each time post-transplant. Symbols are: (—) cyclosporine (N = 250);
(————) no cyclosporine (N = 456).
Of the 706 renal transplants, 9.1 to 11.6% had proteinuria (
0.5 g124 hr) at 3, 6, 12, and 24 months. Proteinuria was more
common in patients who subsequently lost their grafts to chronic
rejection (Table 4), and proteinuria was an independent risk
factor for chronic rejection (Table 3). Similarly, hypoalbuminemia
[< 3.5 g/dl (< 35 g/liter)] and hypertriglyceridemia [ 200 mg/dl
(2.25 mmol/liter)] were more common in patients with chronic
rejection (Table 4), and both were independent risk factors for
chronic rejection (Table 3). The effect of hypertriglyceridemia on
chronic rejection was independent of the presence of pre- and
post-transplant diabetes mellitus, and diabetes itself was not a risk
factor for chronic rejection. Cholesterol and HDL were not
different between patients with and without chronic rejection
during the first 24 months (data not shown), and cholesterol was
not a risk factor for chronic rejection in the Cox analysis.
Although HDL was a risk factor in univariate survival analysis
[0.98 (0.97 to 0.99), P = 0.0471, the effects of HDL were not
independent of triglycerides and other risk factors in the multi-
variate analysis (Table 3). Hypertension, was present in 69 to 74%
of patients from 3 to 24 months, and the degree of hypertension
was a risk factor for chronic rejection in univariate Cox analysis
[1.74 (1.30 to 2.13), P < 0.0011. However, the effects of hyperten-
sion were not independent of other risk factors in the multivariate
analysis (Table 3). There was no difference in the incidence of
cytomegalovirus infection in patients who did or did not go on to
lose their grafts to chronic rejection (50% vs. 51%, P = NS).
ytomegalovirus infection was not associated with chronic rejec-
tion in either the univariate or multivariate survival analysis. That
several risk factors for acute rejection, such as the effects of
cadaveric donors, HLA mismatches, high peak panel reactive
antibody (> 50%), symptomatic cytomegalovirus infection, and
the use of conventional immunosuppression (without cyclospo-
rifle) were not independent risk factors for chronic rejection,
suggests that any effects of these variables on chronic rejection
may have been due to their effects on acute rejection.
Since the risk of late graft failure due to chronic rejection is not
equal in cadaveric and living related donor transplants, we
reanalyzed the risk factors for chronic rejection after excluding
living related donor transplants. The risk factors for chronic
rejection in cadaveric donor transplants were similar to the risk
factors shown in Table 3. This is not surprising since only four
kidneys (5%) were lost to chronic rejection among living related
recipients.
Discussion
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Late graft failure due to chronic rejection is emerging as one of
the major challenges to the future of renal transplantation.
Unfortunately, the pathogenesis of chronic rejection is poorly
understood. The most consistently identified risk factor for
chronic renal allograft rejection has been the occurrence of acute
rejection episodes [7, 11—13]. Although our results confirm the
central role of acute rejection in predicting graft failure from
chronic rejection, they also demonstrate that not all acute rejec-
tion episodes lead to chronic rejection. In particular, acute
rejection episodes occurring in the first three months after
transplantation were not associated with an increased risk for
chronic rejection (Table 2). Even more severe acute rejection
episodes, defined by a greater than 50% reduction in renal
function, conveyed only a modest increase in the risk for chronic
rejection when they occurred in the first three months.
These data suggest a possible explanation for the paradoxical
observation that, although cyclosporine effectively reduces acute
rejection [14—16], and acute rejection predicts chronic rejection
[7, 11—13, 28, 29], cyclosporine does not prevent chronic rejection
[3—5, 17]. At least one other investigation has found that acute
rejection episodes during the first three months after transplan-
tation do not predict chronic rejection [30]. Thus, it is possible
that cyclosporine may not prevent chronic rejection because the
acute rejection episodes during the first three months after
transplantation that cyclosporine most effectively prevents do not
cause chronic rejection.
Alternatively, it is possible that adverse effects of cyclosporine
counteract any benefit from preventing acute rejection during the
first three months after transplantation. However, since cyclospo-
rine was discontinued in most patients around one year post-
transplant, chronic adverse effects of cyclosporine seem unlikely
in our population. It is theoretically possible that acute rejection
from cyclosporine withdrawal counterbalanced any beneficial
effects from fewer acute rejection episodes during the first three
months after transplantation, and resulted in the failure of
cyclosporine to prevent chronic rejection. However, the incidence
of acute rejection episodes following cyclosporine withdrawal was
similar to the incidence in patients who never used cyclosporine,
and a careful analysis of the effects of cyclosporine withdrawal and
post-withdrawal acute rejections showed no effect on chronic
rejection. These data are consistent with the results of a recent
randomized controlled trial which demonstrated that cyclosporine
withdrawal had no effect on chronic rejection after long-term
follow-up [31].
Our results demonstrate that acute rejection episodes occurring
more than two years after transplantation are particularly strong
predictors of chronic rejection (Table 2). Others have also found
acute rejection occurring one year after transplantation to be
associated with a high risk of chronic rejection [11, 32]. Whether
acute rejection occurring one or two years after transplantation is
due to poor adherence to medications [33], to suboptimal immu-
nosuppression, or to other factors is unclear. Also unclear is the
extent to which acute rejection occurring more than one or two
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Variable
Univariate
analysis P value
Multivariate
analysis P value
Age (each decade) 0.83 (0.71—0.96) 0.011 0.74 (0.63—0.89) 0.001
Each acute rejection 2.38 (2.21—2.60) 0.000 2.31 (2.04—2.60) 0.000
episode
Each severe acute 1.36 (1.14—1.6) 0.000 1.53 (1.27—1.84) 0.000
rejection episode
Serum albumin 0.15 (0.09—0.23) 0.000 0.20 (0.10—0.38) 0.000
(each g/dl)
Proteinuria (each 1.55 (1.43—1.64) 0.000 1.42 (1.29—1.57) 0.000
g124h)
Serum triglyceride 1.07 (1.01—1.14) 0.005 1.09 (1.03—1.16) 0.034
(each 100 mg/dl)
years after transplantation is distinguishable from chronic rejec-
tion, either functionally (acute vs. chronic deterioration in renal
function), or histologically (tubulitis superimposed on chronic
rejection), and also the clinical relevance of this mixed pattern.
However, what is clear is the need to develop new strategies to
reduce the incidence of acute rejection occurring more than one
year after transplantation if we are to improve long-term graft
survival [33, 341.
Our results also demonstrate that the severity of acute rejec-
tion, as reflected in the relative decline in renal function, is an
independent risk factor for chronic rejection. The severity of acute
rejection episodes, evaluated by histological markers of acute
vascular rejection, has also previously been reported to predict
subsequent graft failure [24, 35]. Thus, the present results may be
consistent with these previous studies concerning the severity of
Fig. 2. Association between cyclosporine and
presence or absence of first acute rejection
(Kaplan-Meier plot). Cyclosporine versus no
cyclosporine indicates patients who were or
were not initially treated with prophylactic
cyclosporine after transplantation regardless of
subsequent imrnunosuppression, that is, by
intention to treat. Numbers indicate the
1 0 number of patients analyzed at each time post-
transplant. Symbols are: (—) cyclosporine (N
= 250); (————) no cyclosporine (N = 456).
acute rejection. In addition, these results also suggest that the
failure of cyclosporine and other prophylactic immunosuppres-
sion to prevent chronic rejection may be directly attributable to a
failure to prevent this subset of more severe acute rejection
episodes.
The degree of HLA mismatch has not consistently been found
to be an important determinant of chronic rejection [7, 12, 36, 37].
The close correlation between HLA mismatching and acute
rejection in our study, and reported by others [37], may make it
difficult to demonstrate an independent association between HLA
mismatches and chronic rejection if the detrimental effects of
HLA mismatches are manifest in late acute rejection episodes. In
addition, we cannot ignore the possibility that the uniformity in
the HLA matching of our patients made it difficult to demonstrate
an effect of matching on chronic rejection. Indeed, 64% of our
patients had zero DR mismatches.
The results of the present study also suggest that at least some
risk factors for chronic rejection may not be directly linked to
immune system activity. In agreement with the results of others,
proteinuria was found to be an independent risk factor for chronic
rejection [9, 10, 16, 38, 39]. Whether proteinuria is merely a
marker of chronic rejection, or whether proteinuria itself contrib-
utes to the pathogenesis of renal injury in chronic rejection
[40—42], is unclear.
There have been few investigations examining the relationship
between lipids and chronic rejection. Many have reported, asso-
ciations between pre- or post-transplant cholesterol and chronic
rejection [8, 43—46]. However, none have examined large numbers
of patients with a multivariate analysis of multiple post-transplant
risk factors. In the present analysis triglycerides were most closely
associated with chronic rejection. Since triglyceride and HDL
metabolism are linked, the fact that the effects of HDL were not
independent of triglycerides does not exclude a possible role for
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Table 3. Independent risk factors for chronic injectiona
113 91 74
2 8
A relative risk greater or less then 1.00 indicates a proportionally higher
or lower risk of losing a graft to chronic rejection, respectively.
a Relative risk (no risk = 1.00) and (in parentheses) 95% confidence
interval for univariate and multivariate Cox proportional hazard models.
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Table 4. Relationship between serum albumin, triglycerides, and proteinuria and chronic rejectiona
Time after transplantation
CR
Number of
transplants
No CR
Percent with
hypoalbuminemia
CR
Percent with
proteinuria
No CR
Percent with
hypertriglyceridemia
months CR No CR CR No CR
3 126 580 25 23 21 6' 41 36
6 126 580 14 10 20 6b 41 39
12 109 564 15 7C 21 8h 46 33h
24 94 531 13 7 28 8h 45 27h
60 48 390 26 9b 40 15b 28 28
a Numbers of patients with and without CR, percent of patients with hypoalbuminemia [<3.5 g/dl (<35 gIliter), hypertriglyceridemia [200 mg/dl
(2.25 mmol/liter)] and proteinuria (500 mg/24 hr). Abbreviation is CR, chronic rejection.
hp < 0.01 vs. CR
P < 0.02 vs. CR
both. Although the effects of triglycerides on chronic rejection
were independent of many risk factors known to raise triglycer-
ides, it is still possible that the association was an effect rather than
a cause of chronic rejection. Whether triglycerides play a direct
role on progression of chronic rejection, reflect other potentially
harmful defects in lipoproteins, or reflect more generalized
metabolic abnormalities is unclear.
It has been reported that transplant recipients with higher
blood pressure had greater rates of renal function decline than
patients with lower arterial pressure [20, 45, 47]. Indeed, we found
hypertension to be a risk factor for chronic rejection in univariate
survival analysis. However, the effects of hypertension were not
independent of the other risk factors in the multivariate analysis.
Interestingly, it was recently reported that hypertension was an
important predictor of chronic rejection in African Americans but
not in Caucasians [21]. There were few African Americans in our
study population.
A potentially important result of the present study is our finding
that serum albumin was an independent risk factor for graft loss
to chronic rejection. Serum albumin has not previously been
reported to be an independent risk factor for chronic renal
allograft rejection. Although the mechanism for this association
cannot be discerned from these data, it is noteworthy that it was
independent of age, proteinuria, acute rejection episodes, and
other factors that would readily explain it. Clearly, additional
studies are needed to better define the potential role of serum
albumin.
As with any retrospective study the present results should be
interpreted with caution. In a retrospective analysis, it is always
difficult to know when clinical associations represent true cause
and effect relationships. In addition, unaccounted differences in
treatment protocols or patients populations may make it difficult
to extend our results to other centers. Nevertheless, our results
suggest a number of immune and nonimmune factors that may be
risk factors for chronic rejection. These factors may help to define
patients who are most likely to develop chronic renal allograft
rejection, and may make it possible to select high risk patients for
potential therapeutic intervention.
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